To this end, the dual BCL2/BCL-XL inhibitor AZD4320 has been further developed as a PEGylated poly-lysine dendrimer conjugate.438 With a size of only 7–15 nm, the resulting dendrimer conjugate, AZD0466, is a small nanoparticle with good tumor penetration ability and a favorable therapeutic index.439 A first-in-human clinical trial indicated good tolerability of AZD0466 in patients with advanced solid tumors (NCT04214093). This evidence concerns the gene BCL2L1 and neoplasm.